Comparison of Hyaluronidase-Mediated Degradation Kinetics of Commercially Available Hyaluronic Acid Fillers In Vitro (2024)

Article Navigation

Article Contents

  • Abstract

Journal Article Accepted manuscript

,

Jimmy Faivre, PhD

Research manager

,

Teoxane SA, Geneva

,

Switzerland

Search for other works by this author on:

Oxford Academic

,

Kevin Wu, PharmD

Revance Therapeutics, Inc.

,

Nashville, TN

,

USA

Search for other works by this author on:

Oxford Academic

,

Mélanie Gallet, BSc

R&D Technician

,

Teoxane SA, Geneva

,

Switzerland

Search for other works by this author on:

Oxford Academic

,

Julia Sparrow, PhD

Revance Therapeutics, Inc.

,

Nashville, TN

,

USA

Search for other works by this author on:

Oxford Academic

,

François Bourdon, M Eng

R&D director

,

Teoxane SA, Geneva

,

Switzerland

Search for other works by this author on:

Oxford Academic

Conor J Gallagher, PhD

Medical Affairs and Scientific Innovation, Revance Therapeutics, Inc.

,

Nashville, TN

,

USA

Corresponding Author: Dr Conor J. Gallagher, Medical Affairs, Revance Therapeutics, Inc., 7555 Gateway Blvd, Newark, CA, 94560 USA, Email: cgallagher@revance.com

Search for other works by this author on:

Oxford Academic

Aesthetic Surgery Journal, sjae032, https://doi.org/10.1093/asj/sjae032

Published:

16 February 2024

Article history

Received:

23 December 2023

Revision received:

01 February 2024

Accepted:

05 February 2024

Published:

16 February 2024

  • PDF
  • Split View
  • Views
    • Article contents
    • Figures & tables
    • Video
    • Audio
    • Supplementary Data
  • Cite

    Cite

    Jimmy Faivre, Kevin Wu, Mélanie Gallet, Julia Sparrow, François Bourdon, Conor J Gallagher, Comparison of Hyaluronidase-Mediated Degradation Kinetics of Commercially Available Hyaluronic Acid Fillers In Vitro, Aesthetic Surgery Journal, 2024;, sjae032, https://doi.org/10.1093/asj/sjae032

    Close

Search

Close

Search

Advanced Search

Search Menu

Abstract

Background

Hyaluronic acid (HA)-based fillers are degradable with hyaluronidase, which allows for better management of adverse effects and reversal of suboptimal treatment outcomes.

Objectives

To compare the enzymatic degradation kinetics of 16 commercially available HA-based fillers, representing 6 manufacturing technologies.

Methods

In this nonclinical study, a recently developed in vitro multidose hyaluronidase administration protocol was used to induce degradation of HA-based fillers, which allowed for real-time evaluation of viscoelastic properties at near static conditions. Each filler was exposed to repeated doses of hyaluronidase at intervals of 5 minutes to reach the degradation threshold of G’ ≤ 30 Pa.

Results

Noticeable differences in degradation characteristics were observed based on the design and technology of different filler classes. Vycross fillers were the most difficult to degrade and the Cohesive Polydensified Matrix filler was the least difficult to degrade. Preserved Network Technology products demonstrated proportional increases in gel degradation time and enzyme volume required for degradation across the individual RHA products and indication categories. No obvious relationship was observed between gel degradation characteristics and the individual parameters of HA concentration, HA chain length, or the degree of modification of each filler when analyzed separately; however, a general correlation was identified with certain physicochemical properties.

Conclusions

Manufacturing technology was the most important factor influencing the reversibility of an HA product. An understanding of the differential degradation profiles of commercially available fillers will allow clinicians to select products that offer a higher margin of safety due to their preferential reversibility.

Comparison of Hyaluronidase-Mediated Degradation Kinetics of Commercially Available Hyaluronic Acid Fillers In Vitro (3) Accepted manuscripts

Accepted manuscripts are PDF versions of the author’s final manuscript, as accepted for publication by the journal but prior to copyediting or typesetting. They can be cited using the author(s), article title, journal title, year of online publication, and DOI. They will be replaced by the final typeset articles, which may therefore contain changes. The DOI will remain the same throughout.

PDF

This content is only available as a PDF.

© The Author(s) 2024. Published by Oxford University Press on behalf of The Aesthetic Society.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

Topic:

  • rheumatoid arthritis
  • gel
  • hyaluronic acid
  • hyaluronidase
  • safety
  • technology
  • enzymes
  • kinetics
  • treatment outcome
  • catabolism

Subject

Cosmetic Medicine

Issue Section:

Original Article

Download all slides

Advertisem*nt

Citations

Views

39

Altmetric

More metrics information

Metrics

Total Views 39

0 Pageviews

39 PDF Downloads

Since 2/1/2024

Month: Total Views:
February 2024 39

Citations

Powered by Dimensions

Altmetrics

×

Email alerts

Article activity alert

Advance article alerts

New issue alert

Subject alert

Receive exclusive offers and updates from Oxford Academic

More on this topic

Long-term Prognosis of Vision Loss Caused by Facial Hyaluronic Acid Injections and the Potential Approaches to Address This Catastrophic Event

Efficacy of Percutaneous Superficial Temporal Arterial Hyaluronidase Injection for Hyaluronic Acid Filler–Induced Necrosis of Frontotemporal Skin and/or the Ipsilateral Scalp With Subsequent Alopecia

Efficacy of Percutaneous Intraarterial Facial/Supratrochlear Arterial Hyaluronidase Injection for Treatment of Vascular Embolism Resulting From Hyaluronic Acid Filler Cosmetic Injection

Commentary on: Efficacy of Percutaneous Intraarterial Facial/Supratrochlear Arterial Hyaluronidase Injection for Treatment of Vascular Embolism Resulting From Hyaluronic Acid Filler Cosmetic Injection

Citing articles via

Google Scholar

  • Latest

  • Most Read

  • Most Cited

Revisiting Level of Evidence Ratings in Plastic Surgery: A Call To Action
Deciphering Depressor Anguli Oris for Lower Face Rejuvenation: A Prospective Ultrasound-Based Investigation
Optimizing Implant Width Selection in Breast Augmentation: Insights from On-Patient Landmark Positioning in 3D Breast Simulation
A Prospective, Multicenter, Evaluator-Blind, Randomized, Controlled Study of Belotero Balance (+), a Hyaluronic-Acid Filler with Lidocaine, for Correction of Infraorbital Hollowing in Adults
Comparison of Different Acellular Dermal Matrix in Breast Reconstruction: A Skin-to-Skin Study

More from Oxford Academic

Cosmetic Medicine

Medicine and Health

Plastic and Reconstructive Surgery

Surgery

Books

Journals

Advertisem*nt

Comparison of Hyaluronidase-Mediated Degradation Kinetics of Commercially Available Hyaluronic Acid Fillers In Vitro (2024)

References

Top Articles
Latest Posts
Article information

Author: Mrs. Angelic Larkin

Last Updated:

Views: 5653

Rating: 4.7 / 5 (47 voted)

Reviews: 86% of readers found this page helpful

Author information

Name: Mrs. Angelic Larkin

Birthday: 1992-06-28

Address: Apt. 413 8275 Mueller Overpass, South Magnolia, IA 99527-6023

Phone: +6824704719725

Job: District Real-Estate Facilitator

Hobby: Letterboxing, Vacation, Poi, Homebrewing, Mountain biking, Slacklining, Cabaret

Introduction: My name is Mrs. Angelic Larkin, I am a cute, charming, funny, determined, inexpensive, joyous, cheerful person who loves writing and wants to share my knowledge and understanding with you.